AbbVie (NYSE: ABBV) and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing...
Bristol Myers Squibb (NYSE: BMY) announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio...
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epine...
Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therape...
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. The Fellowships were presented ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual con...
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...
GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...
Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidne...
Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open lette...
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical ...
© 2025 Biopharma Boardroom. All Rights Reserved.
